Glioblastoma Multiforme Treatment Market

Glioblastoma Multiforme Treatment Market by Therapy Types (Radiosensitizers, Temozolomide, Bevacozumab, Carmustine, Chemotherapy, and Others) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-2604
  • Author: Growth Market Reports
  • Rating: 4.7
  • Total Reviews: 2
  • No. Of Pages: 200
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global glioblastoma multiforme treatment market size is projected to register a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing cases of oncology diseases and growing geriatric population globally.

glioblastoma-multiforme-treatment-market

Glioblastoma (GBM) is the most common type of primary tumor of the central nervous system (CNS), affecting predominantly adults. Poor diagnosis has not improved considerably despite there has been rapid development of new therapeutics and innovative diagnostic tools. Moreover, somatic evolution supports cancer progression by causing the cancer cell's genome to diverge from healthy cell due to the mutations. Furthermore, GBM has a remarkable progression caused by a complex network of molecular and genetic abnormalities. GBMs are hazardous in nature as they disseminate widely throughout the parenchyma, making maximal surgical resection impossible and having a high level of vascularization. However, various comprehensive treatments such as surgery, chemotherapy, and radiation, patients with GBM have a median survival period of only 14.6 months. Radical tumor excision is not curative due to its high invasiveness. Furthermore, according to varied experimental data, GBM has a fraction of highly tumorigenic cells from which recurrent GBM is assumed to derive and it has the ability to develop into several tumor genesis lineages.

Due to the COVID-19 pandemic outbreak, the glioblastoma multiforme treatment market is adversely impacted. However, all major precautions are taken to treat GBM, followed by prescribed guidelines. Alternatively, patients are encouraged telemedicine consultation for follow-ups, and hospitals & clinics are minimizing the contacts between patients & staffs for the treatment.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing government measures to expand the industry and encouraging regulatory policies are likely to upsurge the market growth in the coming years.
  • Rising R&D activities in molecular biotechnology and gene therapy for the treatment of central nervous system associated disorders and cancer are anticipated to fuel the market growth.
  • Lack of reimbursement policies and high cost involved treatment procedure are expected to restrain the market growth.
  • Various side effects associated with therapies are one of the key restraining factors challenging the market growth.
  • Increasing collaboration among key healthcare companies and research institutes to develop advanced therapies for hematologic malignancies, which is projected to expand the market growth during the forecast period.

Scope of the Report

The report on the global glioblastoma multiforme treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Glioblastoma Multiforme Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Therapy Types (Radiosensitizers, Temozolomide, Bevacozumab, Carmustine, Chemotherapy, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Teva Pharmaceutical Industries, Ltd.; Merck & Co., Inc.; Sun Pharmaceutical Industries, Ltd.; F. Hoffmann-Le Roche AG; and Arbor Pharmaceuticals LLC.

Market Segment Insights

Chemotherapy segment is expected to grow at a rapid pace

Based on therapy types, the global glioblastoma multiforme treatment market is segmented into radiosensitizers, temozolomide, bevacozumab, carmustine, chemotherapy, and others. The chemotherapy segment is expected to grow at a rapid pace during the forecast period owing to the increasing incidence of brain and other nervous system cancers. The chemotherapy operations have a significantly greater success rate than other treatment modalities currently available, which is a key reason fueling the segment growth.

Furthermore, the profitable nature of the chemotherapy business as well as the sector's projected development potential have inspired big pharmaceutical corporations and independent investors to enter the market. Thus, aforementioned factors are estimated to boost the segment growth during the forecast period.

glioblastoma-multiforme-treatment-market-by-type

North America is anticipated to constitute a key market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the forecast period due to the growing biopharmaceutical research and rising number of the central nervous system cancers in the geriatric population. Furthermore, non-governmental and governmental support, presence of numerous vaccine products, rapid clinical trials for treatment of glioblastoma multiforme, and the presence of key pharmaceutical companies are expected to boost the market expansion in the region.

Moreover, health organizations such as the Brain Tumor Foundation of Canada (BTFC), the National Brain Tumor Society (NBTS), and the American Brain Tumor Association (ABTA) are conducting various awareness campaign related to GBM, resulting in market growth during the forecast period in the region. According to the National Cancer Institute of the United States, GBM is the most aggressive kind of brain cancer, accounting for 15.4% of all primary brain tumors and 60% to 75% of all astrocytoma.

glioblastoma-multiforme-treatment-market-analysis-by-region

Segments

Segments Covered in the Report

The global glioblastoma multiforme treatment market has been segmented on the basis of

Therapy Types

  • Radiosensitizers
  • Temozolomide
  • Bevacozumab
  • Carmustine
  • Chemotherapy
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

Competitive Landscape

Some of the major players competing in the global glioblastoma multiforme treatment market are Teva Pharmaceutical Industries, Ltd.; Merck & Co., Inc.; Sun Pharmaceutical Industries, Ltd.; F. Hoffmann-Le Roche AG; and Arbor Pharmaceuticals LLC. Most of these big players are implementing various marketing strategies such as partnerships, mergers & acquisitions, collaboration, and extensive service portfolio along with expanding service capacity on various geographies to secure substantial position.

Glioblastoma Multiforme Treatment Market

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Glioblastoma Multiforme Treatment Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Glioblastoma Multiforme Treatment Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Glioblastoma Multiforme Treatment Market - Supply Chain
  4.5. Global Glioblastoma Multiforme Treatment Market Forecast
     4.5.1. Glioblastoma Multiforme Treatment Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Glioblastoma Multiforme Treatment Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Glioblastoma Multiforme Treatment Market Absolute $ Opportunity
5. Global Glioblastoma Multiforme Treatment Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Glioblastoma Multiforme Treatment Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Glioblastoma Multiforme Treatment Demand Share Forecast, 2019-2026
6. North America Glioblastoma Multiforme Treatment Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Glioblastoma Multiforme Treatment Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Glioblastoma Multiforme Treatment Demand Share Forecast, 2019-2026
7. Latin America Glioblastoma Multiforme Treatment Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Glioblastoma Multiforme Treatment Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Glioblastoma Multiforme Treatment Demand Share Forecast, 2019-2026
8. Europe Glioblastoma Multiforme Treatment Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Glioblastoma Multiforme Treatment Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Glioblastoma Multiforme Treatment Demand Share Forecast, 2019-2026
9. Asia Pacific Glioblastoma Multiforme Treatment Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Glioblastoma Multiforme Treatment Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Glioblastoma Multiforme Treatment Demand Share Forecast, 2019-2026
10. Middle East & Africa Glioblastoma Multiforme Treatment Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Glioblastoma Multiforme Treatment Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Glioblastoma Multiforme Treatment Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Glioblastoma Multiforme Treatment Market: Market Share Analysis
  11.2. Glioblastoma Multiforme Treatment Distributors and Customers
  11.3. Glioblastoma Multiforme Treatment Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)

Segments Covered in the Report

The global glioblastoma multiforme treatment market has been segmented on the basis of

Therapy Types

  • Radiosensitizers
  • Temozolomide
  • Bevacozumab
  • Carmustine
  • Chemotherapy
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

Some of the major players competing in the global glioblastoma multiforme treatment market are Teva Pharmaceutical Industries, Ltd.; Merck & Co., Inc.; Sun Pharmaceutical Industries, Ltd.; F. Hoffmann-Le Roche AG; and Arbor Pharmaceuticals LLC. Most of these big players are implementing various marketing strategies such as partnerships, mergers & acquisitions, collaboration, and extensive service portfolio along with expanding service capacity on various geographies to secure substantial position.

Glioblastoma Multiforme Treatment Market

Buy Report